Can­cer cell-based ther­a­pies com­ing in­to 'im­por­tan­t' year for R&D, say SVB an­a­lysts

De­spite in­vestor doubt in al­lo­gene­ic cell ther­a­py, 2023 will be an “im­por­tant” year for both au­tol­o­gous and al­lo­gene­ic im­mune-cell-based ther­a­pies in mul­ti­ple myelo­ma and non-Hodgkin’s lym­phoma, SVB an­a­lysts pre­dict.

With drug can­di­dates like mo­sune­tuzum­ab, glofi­ta­m­ab and ep­cori­ta­m­ab mak­ing their way through clin­i­cal tri­als, SVB Se­cu­ri­ties an­a­lysts are pre­dict­ing the com­mer­cial­iza­tion of bis­pe­cif­ic CD3 T-cell en­gagers will be­gin to be a part of treat­ment par­a­digms as these drugs get ap­proved.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.